Inactive Instrument

News Ultima Networks plc London S.E.

Stocks

GB0005895098

Biotechnology & Medical Research

End-of-day quote London S.E. Other stock markets
- ^GBX	-

07-01	Thalia Therapeutics Plc - Special Call
06-24	Tullow Oil makes partial notes repayment	AN

All News

Mentions Relevance

07-01	Thalia Therapeutics Plc - Special Call
06-24	Thalia Therapeutics Plc agreed to acquire Sanmirna Therapeutics Inc from NLC Ventures Netherlands B.V., NLC Health Impact Fund, David Solomon and City Of Hope.	CI
06-24	Thalia Therapeutics to Buy Sanmirna Therapeutics; Conditionally Raises Funds	MT
06-24	Thalia Therapeutics PLC Announces Acquisition and £2.75 Million Fundraise	AQ
06-23	Thalia Therapeutics Plc Auditor Raises 'Going Concern' Doubt	CI
06-23	Thalia Therapeutics eyes adding microRNA therapeutic asset	AN
06-23	Thalia Therapeutics Plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
06-08	Thalia Therapeutics Plc - Special Call
05-19	Thalia Therapeutics Plc - Special Call
04-20	Thalia Therapeutics plc Announces Change of Registered Address	CI
04-06	Thalia Therapeutics Plc - Special Call
03-17	N4 Pharma Plc will Change its Ticker to THAT from N4P	CI
03-17	N4 Pharma Plc will Change its Name to Thalia Therapeutics plc	CI
03-17	N4 Pharma shareholders pass resolution to change co name to Thalia Therapeutics	RE
03-17	N4 Pharma Shareholders Approve Name Change to Thalia Therapeutics	MT
02-27	N4 Pharma proposes name change to Thalia Therapeutics	RE
02-24	N4 Pharma to Rebrand as Thalia Therapeutics	MT
02-24	N4 Pharma plc appoints David H Solomon as CEO	RE
02-24	N4 Pharma plc Announces CEO Changes	CI
02-24	Nigel Theobald Steps Down as Director of N4 Pharma Plc, Effective from 24 February 2026	CI
25-09-26	N4 Pharma Plc, H1 2025 Earnings Call, Sep 25, 2025
25-09-25	N4 Pharma : Interim Results - 2025 (250925 N4 Pharma Interim Results RNS Final lnozqn)	PU
25-09-25	N4 Pharma Plc Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-09-25	Earnings Flash (N4P.L) N4 Pharma Reports H1 Revenue GBP3,690	MT
25-09-23	N4 Pharma teams up with University of Strathclyde facility	AN